Probing binding requirements of NAD kinase with modified substrate (NAD) analogues

Bioorg Med Chem Lett. 2007 Mar 15;17(6):1512-5. doi: 10.1016/j.bmcl.2007.01.012. Epub 2007 Jan 17.

Abstract

Synthesis of novel NAD(+) analogues that cannot be phosphorylated by NAD kinase is reported. In these analogues the C2' hydroxyl group of the adenosine moiety was replaced by fluorine in the ribo or arabino configuration (1 and 2, respectively) or was inverted into arabino configuration to give compound 3. Compounds 1 and 2 showed inhibition of human NAD kinase, whereas analogue 3 inhibited both the human and Mycobacterium tuberculosis NAD kinase. An uncharged benzamide adenine dinucleotide (BAD) was found to be the most potent competitive inhibitor (K(i)=90 microM) of the human enzyme reported so far.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Benzamides / chemical synthesis
  • Benzamides / pharmacology
  • Enzyme Inhibitors / chemical synthesis*
  • Enzyme Inhibitors / pharmacology*
  • Humans
  • Magnesium / physiology
  • Molecular Conformation
  • Mycobacterium tuberculosis / enzymology
  • NAD / analogs & derivatives*
  • NAD / pharmacology*
  • Phosphorylation
  • Phosphotransferases (Alcohol Group Acceptor) / antagonists & inhibitors*
  • Structure-Activity Relationship

Substances

  • Benzamides
  • Enzyme Inhibitors
  • NAD
  • Phosphotransferases (Alcohol Group Acceptor)
  • NAD kinase
  • Magnesium